Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

Nicki Niemann; Joseph Jankovic

首页> 外文期刊>Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts >Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

【24h】

Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

机译：纠正：Tardive Dyskinesia的治疗：一般概述，重点在凹凸单胺转运蛋白2抑制剂上

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The dose (mg/day) for Clonazepam which reads:

机译：克隆泮的剂量（mg /天）读取：

著录项

来源
《Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts》 |2018年第5期|共1页
作者
Nicki Niemann; Joseph Jankovic;
展开▼
作者单位

Parkinson’s Disease Center and Movement Disorders Clinic Department of Neurology Baylor College;

Parkinson’s Disease Center and Movement Disorders Clinic Department of Neurology Baylor College;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors [J] . Nicki Niemann, Joseph Jankovic Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts . 2018,第5期

机译：纠正：Tardive Dyskinesia的治疗：一般概述，重点在凹凸单胺转运蛋白2抑制剂上
2. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management [J] . Venkatesh Sreeram, Shanila Shagufta, Faisal Kagadkar Cureus. . 2019,第8期

机译：尿素单胺转运蛋白2抑制剂在Tardive Dyskinesia管理中的作用
3. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective [J] . Citrome, L. Expert review of neurotherapeutics . 2018,第1a6期

机译：Tardive Dyskinesia：将凹凸单胺转运蛋白2（VMAT2）抑制剂放入临床视角
4. Design, synthesis, and pharmacological evaluation of three series of lobelane analogs as inhibitors of the vesicular monoamine transporter (VMAT2). [D] . Culver, John P. 2015

机译：设计，合成和药理学评估三个系列的环氧丙烷类似物作为水泡单胺转运蛋白（VMAT2）的抑制剂。
5. Vesicular monoamine transporter inhibitors versus placebo for antipsychotic‐induced tardive dyskinesia [O] . Boris Karl, Hanna Bergman, Sarah Abd El Sayed, -1

机译：水泡单胺转运蛋白抑制剂与安慰剂的抗精神病药性迟发性运动障碍
6. Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors [O] . Stanley N. Caroff 2020

机译：尿形单胺转运蛋白抑制剂的神经抑制性恶性综合征风险
7. THE APPLICATION OF A MONOAMINE OXIDASE INHIBITOR 1-PHENYL-2-HYDRAZINOPROPANE (JB-516), TO THE TREATMENT OF PRIMARY HYPERTENSION [R] . Louis Gillespie, Luther L. Terry, Albert Sjoerdsma 1960

机译：单胺氧化酶抑制剂1-苯基-2-肼基丙烷（JB-516）在原发性高血压治疗中的应用

Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

摘要

著录项

相似文献

相关主题

期刊订阅